PriceTargets.com logo

Celcuity - CELC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.17
  • Forecasted Upside: 128.22%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$12.78 As of 11/20/2024 01:00 AM ET
▲ +0.31 (2.49%)

This chart shows the closing price for CELC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celcuity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELC

Analyst Price Target is $29.17
▲ +128.22% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Celcuity in the last 3 months. The average price target is $29.17, with a high forecast of $42.00 and a low forecast of $23.00. The average price target represents a 128.22% upside from the last price of $12.78.

This chart shows the closing price for CELC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 contributing investment analysts is to buy stock in Celcuity.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
11/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
10/7/2024Stifel NicolausBoost TargetBuy ➝ Buy$39.00 ➝ $42.00
8/26/2024Lifesci CapitalInitiated CoverageOutperform$27.00
8/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
8/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
8/15/2024Stifel NicolausLower TargetBuy ➝ Buy$40.00 ➝ $39.00
7/22/2024Leerink PartnrsUpgradeStrong-Buy
7/22/2024Leerink PartnersInitiated CoverageOutperform$29.00
5/31/2024Needham & Company LLCLower TargetBuy ➝ Buy$24.00 ➝ $23.00
5/16/2024Stifel NicolausReiterated RatingBuy ➝ Buy$40.00
5/16/2024Craig HallumReiterated RatingBuy$25.00 ➝ $27.00
5/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
5/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00
3/28/2024Craig HallumBoost TargetBuy ➝ Buy$20.00 ➝ $25.00
3/28/2024Needham & Company LLCBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
3/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
2/22/2024Stifel NicolausInitiated CoverageBuy$40.00
12/8/2023HC WainwrightInitiated CoverageBuy$27.00
11/13/2023Needham & Company LLCLower TargetBuy ➝ Buy$25.00 ➝ $23.00
9/22/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$25.00
5/17/2022Craig HallumLower TargetNA$30.00 ➝ $20.00
9/7/2021Jefferies Financial GroupInitiated CoverageBuy$48.00
8/10/2021Needham & Company LLCInitiated CoverageBuy$50.00
7/29/2021CowenInitiated CoverageOutperform
7/27/2021Needham & Company LLCInitiated CoverageBuy$50.00
4/12/2021HC WainwrightBoost TargetBuy$19.00 ➝ $30.00
2/17/2021Craig HallumBoost TargetBuy$19.00 ➝ $24.00
2/17/2021HC WainwrightReiterated RatingBuy$18.00 ➝ $19.00
1/28/2021HC WainwrightBoost TargetBuy$14.00 ➝ $18.00
12/24/2020Craig HallumBoost TargetBuy$16.00 ➝ $19.00
12/24/2020HC WainwrightBoost TargetBuy$11.00 ➝ $14.00
8/11/2020HC WainwrightReiterated RatingBuy$11.00
7/14/2020HC WainwrightReiterated RatingBuy$11.00
6/23/2020HC WainwrightReiterated RatingBuy$11.00
5/11/2020Craig HallumInitiated CoverageBuy
5/8/2020HC WainwrightReiterated RatingBuy$19.00 ➝ $11.00
3/13/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $19.00
12/13/2019HC WainwrightReiterated RatingBuy$36.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 10 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Celcuity logo
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $12.78
Low: $12.08
High: $13.00

50 Day Range

MA: $15.03
Low: $12.46
High: $16.35

52 Week Range

Now: $12.78
Low: $11.51
High: $22.19

Volume

261,712 shs

Average Volume

280,285 shs

Market Capitalization

$474.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Celcuity?

The following Wall Street analysts have issued research reports on Celcuity in the last year: Craig Hallum, HC Wainwright, Leerink Partners, Leerink Partnrs, Lifesci Capital, Needham & Company LLC, and Stifel Nicolaus.
View the latest analyst ratings for CELC.

What is the current price target for Celcuity?

0 Wall Street analysts have set twelve-month price targets for Celcuity in the last year. Their average twelve-month price target is $29.17, suggesting a possible upside of 128.2%. Stifel Nicolaus has the highest price target set, predicting CELC will reach $42.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $23.00 for Celcuity in the next year.
View the latest price targets for CELC.

What is the current consensus analyst rating for Celcuity?

Celcuity currently has 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CELC will outperform the market and that investors should add to their positions of Celcuity.
View the latest ratings for CELC.

What other companies compete with Celcuity?

Other companies that are similar to Celcuity include Renalytix, Fortrea, Viridian Therapeutics, Teladoc Health and AdaptHealth. Learn More about companies similar to Celcuity.

How do I contact Celcuity's investor relations team?

Celcuity's physical mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The company's listed phone number is (763) 392-0767. The official website for Celcuity is www.celcuity.com. Learn More about contacing Celcuity investor relations.